Merck Reports Phase 3 TroFuse-005 Trial Shows Sac-TMT Improves Overall And Progression-Free Survival, Meeting Both Dual Primary And Key Secondary Endpoints Of ORR In Advanced Or Recurrent Endometrial Cancer; FDA Priority Review Accepted

Loading news article.

Merck Reports Phase 3 TroFuse-005 Trial Shows Sac-TMT Improves Overall And Progression-Free Survival, Meeting Both Dual Primary And Key Secondary Endpoints Of ORR In Advanced Or Recurrent Endometrial Cancer; FDA Priority Review Accepted | WAPE

Merck Reports Phase 3 TroFuse-005 Trial Shows Sac-TMT Improves Overall And Progression-Free Survival, Meeting Both Dual Primary And Key Secondary Endpoints Of ORR In Advanced Or Recurrent Endometrial Cancer; FDA Priority Review Accepted

Article summary

Related companies

Comments —